Akari Therapeutics Plc (AKTX)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-03-16

Key Insights

  • The reporting person, James R. Neal, acquired pre-funded warrants and accompanying warrants to purchase up to 4,946 American Depositary Shares (ADSs) of Akari Therapeutics Plc on December 16, 2025 in a private placement transaction.
  • The reporting person also acquired pre-funded warrants and warrants to purchase up to 6,186 ADSs in exchange for cancellation of an outstanding promissory note held by the reporting person.
  • All of the acquired warrants and pre-funded warrants are subject to shareholder approval and have five-year terms or are exercisable until fully exercised.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Akari Therapeutics Plc filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.